Hospital acquired gram positive infections linked to increased mortality in cirrhosis patients admitted to ICU: Study

Written By :  Jacinthlyn Sylvia
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-05-08 14:45 GMT   |   Update On 2024-05-08 14:46 GMT

A recent study published in the recent issue of Annals of Intensive Care shed light on a previously overlooked area of hospital-acquired bloodstream infections in the ICU, especially for patients with cirrhosis.This study was conducted across 101 centers and analyzed data from the Eurobact-2 international cohort study by encompassing a total of 1059 cases of hospital-acquired...

Login or Register to read the full article

A recent study published in the recent issue of Annals of Intensive Care shed light on a previously overlooked area of hospital-acquired bloodstream infections in the ICU, especially for patients with cirrhosis.

This study was conducted across 101 centers and analyzed data from the Eurobact-2 international cohort study by encompassing a total of 1059 cases of hospital-acquired bloodstream infections. This study underlines the increased vulnerability of cirrhotic patients to infections contracted within hospital walls. Cirrhotic patients who accounted for 160 of the cases showed a distinctive epidemiological profile when compared to their non-cirrhotic counterparts.

The variance in infection sources was a crucial finding of this study. While non-cirrhotic patients predominantly suffered from pulmonary infections, cirrhotic patients were more susceptible to abdominal sources that hinted at underlying physiological factors that could possibly influence the infection localization.

Cirrhotic patients expressed a predilection for Gram-positive infections, notably Enterococcus faecium. The prevalence of this pathogen was significantly higher among the cirrhotic patients that underlined a potential association between cirrhosis and increased susceptibility to specific pathogens. The association between cirrhosis and Enterococcus faecium infections remained profound even after adjusting for confounding factors which highlighted the distinct microbial landscape within cirrhotic patients.

The study uncovered a concerning trend in mortality rates. Cirrhotic patients afflicted with hospital-acquired bloodstream infections faced a 30% higher risk of mortality when compared to their non-cirrhotic counterparts. This underlines the urgent need for tailored interventions and elevated surveillance protocols to reduce the impact of infections in this vulnerable population.

The findings emphasized the significance of this study in guiding clinical management strategies for critically ill cirrhotic patients. Understanding the unique epidemiological nuances of the infections in cirrhotic patients is critical in improving the patient outcomes and reducing mortality rates

The benefits of this study extend beyond the ICU which prompts a reevaluation of infection prevention and control measures in hospital settings. With increase in the prevalence of cirrhosis, proactive measures that target this high-risk population could yield substantial benefits in reducing the burden of hospital-acquired infections.

Source:

Wozniak, H., Tabah, A., Barbier, F., Ruckly, S., Loiodice, A., Akova, M., Leone, M., Conway Morris, A., Bassetti, M., Arvaniti, K., Ferrer, R., de Bus, L., Paiva, J. A., Bracht, H., Mikstacki, A., Alsisi, A., Valeanu, L., Prazak, J., … Timsit, J.-F. (2024). Hospital-acquired bloodstream infections in critically ill cirrhotic patients: a post-hoc analysis of the EUROBACT-2 international cohort study. In Annals of Intensive Care (Vol. 14, Issue 1). Springer Science and Business Media LLC. https://doi.org/10.1186/s13613-024-01299-x

Tags:    
Article Source : Annals of Intensive Care

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News